Pacira Pharmaceuticals Inc (PCRX)

Fixed asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	638,707	621,403	618,553	613,360	627,091	646,604	609,214	577,203	541,534	491,997	489,092	436,030	429,647	421,097	408,298	435,397	421,026	393,717	372,480	353,983
Property, plant and equipment	US$ in thousands	173,927	175,783	180,310	181,617	183,512	193,646	191,279	189,767	188,401	159,235	153,302	144,822	136,688	125,527	113,297	108,105	104,681	104,856	105,492	107,051
Fixed asset turnover		3.67	3.54	3.43	3.38	3.42	3.34	3.18	3.04	2.87	3.09	3.19	3.01	3.14	3.35	3.60	4.03	4.02	3.75	3.53	3.31

December 31, 2023 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $638,707K ÷ $173,927K
= 3.67

Pacira BioSciences Inc's fixed asset turnover ratio has been gradually increasing over the past eight quarters, indicating a positive trend in the company's efficiency in generating revenue from its fixed assets. The ratio has generally improved from 3.06 in Q1 2022 to 3.88 in Q4 2023. This suggests that the company is utilizing its fixed assets more effectively to generate sales revenue. A higher fixed asset turnover ratio signifies that the company is efficiently managing and utilizing its fixed assets to generate revenue compared to previous periods. Overall, the increasing trend in fixed asset turnover is a positive sign of operational efficiency and effective asset utilization within Pacira BioSciences Inc.